These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19563305)

  • 1. The economic crisis, the Pharmaceutical Benefits Scheme, and the dilemmas of medicines policy.
    Löfgren H
    Aust Health Rev; 2009 May; 33(2):171-5. PubMed ID: 19563305
    [No Abstract]   [Full Text] [Related]  

  • 2. A perspective on Australia's National Medicines Policy.
    Tett SE
    Can J Clin Pharmacol; 2004; 11(1):e28-38. PubMed ID: 15226524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patents, pills and politics: the Australia-United States Free Trade Agreement and the Pharmaceutical Benefits Scheme.
    Harvey K
    Aust Health Rev; 2004 Nov; 28(2):218-26. PubMed ID: 15527402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription-drug prices.
    Frank RG
    N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceuticals issue brief: pharmaceutical assistance programs: year end report--2004.
    Seay M
    Issue Brief Health Policy Track Serv; 2004 Dec; ():1-26. PubMed ID: 15724309
    [No Abstract]   [Full Text] [Related]  

  • 7. When Does FDAMA Section 114 Apply? Ten Case Studies.
    Neumann PJ; Saret CJ
    Value Health; 2015 Jul; 18(5):682-9. PubMed ID: 26297097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Pharmaceutical Benefits Scheme and the shifting paradigm of welfare policy.
    Löfgren H
    Aust Health Rev; 1998; 21(2):111-23. PubMed ID: 10181679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PBS reform - a missed opportunity?
    de Boer R
    Aust Health Rev; 2009 May; 33(2):176-85. PubMed ID: 19563306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic consequences of the maximum allowable cost program to the entire profession of pharmacy.
    Paul SH
    Med Mark Media; 1979 Aug; 14(8):19-26. PubMed ID: 10243270
    [No Abstract]   [Full Text] [Related]  

  • 11. Australia-United States Free Trade Agreement and the Australian Pharmaceutical Benefits Scheme.
    Sainsbury P
    Yale J Health Policy Law Ethics; 2004; 4(2):387-99. PubMed ID: 15536920
    [No Abstract]   [Full Text] [Related]  

  • 12. New federal guidelines for physician-pharmaceutical industry relations: the politics of policy formation.
    Chimonas S; Rothman DJ
    Health Aff (Millwood); 2005; 24(4):949-60. PubMed ID: 16136634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More bills coming due. Although Medicare reform has passed Congress, the final package remains uncertain. And what about the fate of other health legislation?
    Fong T; Tieman J
    Mod Healthc; 2003 Jul; 33(27):28-31. PubMed ID: 12884728
    [No Abstract]   [Full Text] [Related]  

  • 14. Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry.
    Bloor K; Maynard A; Freemantle N
    BMJ; 1996 Jul; 313(7048):33-5. PubMed ID: 8664771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The elderly and drug policy: coming of age.
    Avorn J
    Health Aff (Millwood); 1990; 9(3):6-19. PubMed ID: 2121636
    [No Abstract]   [Full Text] [Related]  

  • 16. Medicare Part D--the product of a broken process.
    Slaughter LM
    N Engl J Med; 2006 Jun; 354(22):2314-5. PubMed ID: 16738267
    [No Abstract]   [Full Text] [Related]  

  • 17. Implications of the Australian guidelines for the United States.
    Freund DA; Evans D; Henry D; Dittus R
    Health Aff (Millwood); 1992; 11(4):202-6. PubMed ID: 1483641
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceuticals in Australia: developments in regulation and governance.
    Lofgren H; Boer Rd
    Soc Sci Med; 2004 Jun; 58(12):2397-407. PubMed ID: 15081192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription drug benefits for seniors and public/private collaboration.
    Brekke M
    Beginnings; 2002; 22(3):11. PubMed ID: 12046112
    [No Abstract]   [Full Text] [Related]  

  • 20. International pharmaceutical spending controls: France, Germany, Sweden, and the United Kingdom.
    Gross DJ; Ratner J; Perez J; Glavin SL
    Health Care Financ Rev; 1994; 15(3):127-40. PubMed ID: 10137794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.